// App-Quantinova.ai

THU0164 : PERFUSE: A FRENCH PROSPECTIVE/RETROSPECTIVE NON-INTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAIIVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; AN INTERIM ANALYSIS

Researchers

Presenter

  • B. Fautrel

Principal Investigators

  • Y. Bouhnik

  • G. Desjeux

  • A. Brigui

  • U. Freudensprung

  • J. Addison

Medical Centers

  • Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France

  • Beaujon Hospital, AP-HP, Paris Diderot University, Clichy, France

  • e-health services, Sanoia, Gemenos, France

  • Shire France SAS, Paris, France

  • Biogen, Baar, Switzerland

  • Biogen Maidenhead United Kingdom

Locations

  • France

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

  • Rheumatoid arthritis

  • Psoriatic arthritis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Infliximab Biosimilar

Outcome

  • N/A

Study Design

  • Non Interventional

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved